Importance of equity in the performance and utilization of diagnostic testing

Panelists discuss how equity is a crucial consideration in biomarker performance, as studies show variations in test utility across racial and demographic groups. IsoPSA has demonstrated consistent performance among African American and White populations, but ongoing evaluation is needed to confirm equitable application.

Panelists discuss how structure-based biomarkers could help close gaps in prostate cancer detection for historically underrepresented groups. However, disparities in access to testing, insurance coverage, and provider awareness remain significant obstacles.

Panelists discuss how future research should focus on addressing these gaps to ensure biomarkers do not unintentionally widen disparities. The goal is to provide all patients, regardless of background, with access to accurate diagnostic strategies that improve outcomes.